<DOC>
	<DOC>NCT00002169</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.</brief_summary>
	<brief_title>A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV infection. Newly diagnosed or first progression of CMV retinitis. Exclusion Criteria Prior Medication: Excluded: Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Placebos</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Cytomegalovirus Retinitis</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>